KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $2.63.

  • Bristol Myers Squibb's Debt to Equity fell 896.55% to $2.63 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.63, marking a year-over-year decrease of 896.55%. This contributed to the annual value of $3.03 for FY2024, which is 12459.92% up from last year.
  • Latest data reveals that Bristol Myers Squibb reported Debt to Equity of $2.63 as of Q3 2025, which was down 896.55% from $2.81 recorded in Q2 2025.
  • Over the past 5 years, Bristol Myers Squibb's Debt to Equity peaked at $3.36 during Q1 2024, and registered a low of $0.87 during Q4 2022.
  • For the 5-year period, Bristol Myers Squibb's Debt to Equity averaged around $1.85, with its median value being $1.29 (2023).
  • Its Debt to Equity has fluctuated over the past 5 years, first plummeted by 1651.68% in 2023, then surged by 18359.2% in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Debt to Equity stood at $1.0 in 2021, then dropped by 13.32% to $0.87 in 2022, then soared by 54.94% to $1.35 in 2023, then soared by 124.6% to $3.03 in 2024, then dropped by 13.08% to $2.63 in 2025.
  • Its last three reported values are $2.63 in Q3 2025, $2.81 for Q2 2025, and $2.85 during Q1 2025.